Mosesson M W, Kaminski M
University of Wisconsin Medical School-Milwaukee Clinical Campus, Sinai Samaritan Medical Center 53233.
Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):475-8. doi: 10.1097/00001721-199010000-00020.
Inhibition of thrombin proteolysis of fibrinogen with D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone (PPACK) results in irreversible inactivation of the thrombin catalytic site, but the PPACK-inhibited thrombin, through its exosite, retains its ability to bind to fibrinogen or fibrin. Hirudin inactivates thrombin at the catalytic site and also inhibits thrombin exosite binding to fibrin or fibrinogen. PPACK or hirudin was added to a clotting mixture of fibrinogen and active thrombin (enzyme:substrate ratio, 1:400 and 1:800) prior to the onset of gelation. Subsequent fibrin assembly was evaluated by turbidity measurements at 350 nm and by determining the fibrin and fibrinogen content of the clots that ultimately formed. Polymerization rates and the fibrin/fibrinogen content of the clots that formed were greater in the PPACK-inhibited system than in the hirudin-inhibited system. Lowering the ionic strength from 0.14 to 0.09 amplified these differences. The results suggest that in addition to its well-recognized role in the proteolytic conversion of fibrinogen to fibrin, thrombin functions as a cofactor in the fibrin assembly process.
用D-苯丙氨酰-L-丙氨酰-L-精氨酸氯甲基酮(PPACK)抑制凝血酶对纤维蛋白原的蛋白水解作用会导致凝血酶催化位点不可逆失活,但PPACK抑制的凝血酶通过其外位点仍保留与纤维蛋白原或纤维蛋白结合的能力。水蛭素在催化位点使凝血酶失活,并且还抑制凝血酶外位点与纤维蛋白或纤维蛋白原的结合。在凝胶化开始之前,将PPACK或水蛭素添加到纤维蛋白原和活性凝血酶的凝血混合物中(酶:底物比例为1:400和1:800)。随后通过在350nm处的浊度测量以及通过测定最终形成的凝块中的纤维蛋白和纤维蛋白原含量来评估纤维蛋白组装。在PPACK抑制的系统中形成的凝块的聚合速率和纤维蛋白/纤维蛋白原含量高于水蛭素抑制的系统。将离子强度从0.14降低到0.09会放大这些差异。结果表明,除了其在纤维蛋白原向纤维蛋白的蛋白水解转化中公认的作用外,凝血酶在纤维蛋白组装过程中还作为辅因子发挥作用。